In Vivo Electroporation Using an Exponentially Enhanced Pulse: A New Waveform
- 1 March 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in DNA and Cell Biology
- Vol. 20 (3) , 183-188
- https://doi.org/10.1089/104454901300069040
Abstract
In vivo electroporation is currently accomplished by one of two types of common waveforms: exponential decay or square-wave pulses. The purpose of this report is to present a new electroporation waveform, the exponentially enhanced pulse (EEP). Pulsing protocols including the EEP resulted in high levels of luciferase expression in muscle and skin, equal to or greater than expression resulting from low-voltage, millisecond square-wave pulses. This high level of expression requires fewer pulses when using an EEP protocol. Therefore, similar or greater plasmid DNA expression levels are obtained using fewer pulses with the EEP protocol than with current protocols. This is the first report of this new waveform and shows the success of using protocols employing the EEP to deliver plasmid DNA to various tissue types.Keywords
This publication has 16 references indexed in Scilit:
- Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivoGene Therapy, 2000
- High-efficiency gene transfer into skeletal muscle mediated by electric pulsesProceedings of the National Academy of Sciences, 1999
- In vivo gene delivery by electroporationAdvanced Drug Delivery Reviews, 1999
- Clinical applications of electrochemotherapyAdvanced Drug Delivery Reviews, 1998
- Gene transfer into muscle by electroporation in vivoNature Biotechnology, 1998
- Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycinCancer, 1998
- In vivo gene electroinjection and expression in rat liverFEBS Letters, 1996
- Antitumor electrochemotherapy: New advances in the clinical protocolCancer, 1996
- Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapyCancer, 1996
- Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trialCancer, 1993